INOMAX hospitals
Manufacturing · New Jersey, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
6 State Route 173, Clinton, New Jersey, ...Phone Number
(908) 238-6600Website
www.inomax.comRevenue
$77 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About INOMAX hospitals
Mallinckrodt Pharmaceuticals specializes in the production of INOmax, a nitric oxide gas for inhalation, primarily aimed at treating term and near-term neonates with hypoxic respiratory failure associated with pulmonary hypertension. Their offerings include innovative delivery systems that emphasize flexibility and automation, along with a comprehensive Total Care service that provides 24/7 support, device education, and technical assistance. The company is committed to improving patient outcomes in neonatal intensive care units (NICUs) through effective treatment solutions and ongoing support. With a legacy of service and reliability, Mallinckrodt continues to be a leader in the market for nitric oxide delivery systems.Explore more
Popular SearchesINOMAX hospitalsIno Therapeutics IncIno Therapeutics LLCINO TherapeuticsInomaxSIC Code 28,283NAICS Code 32,325Show moreINOMAX hospitals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is INOMAX hospitals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once INOMAX hospitals has new funding data
Check if INOMAX hospitals has recently received funding, and reach out quickly before it becomes old news!
INOMAX hospitals, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if INOMAX hospitals is spiking on competitors!
Click to see if INOMAX hospitals had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when INOMAX hospitals launches new products
Earning: See what the market has to say on INOMAX hospitals recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at INOMAX hospitals
Recommended Actions
Reach out to Masked Content who joined INOMAX hospitals as Masked Content
Find 3 more new buyers
Compare Similar Companies to INOMAX hospitals
Compare insights from companies similar to INOMAX hospitals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$23M
51-200
Private
-
-
EA
Erin ArcarioDirector, US People Analytics and Human Resources Projects and Chief of Staff
Company Profile Activity
Activity Insights
INOMAX hospitals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
INOMAX hospitals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about INOMAX hospitals.
INOMAX hospitals Tech Stack
A closer look at the technologies used by INOMAX hospitals
See more technologies
INOMAX hospitals News & Media
Mallinckrodt Announces FDA Clearance of the INOmax® EVOLVE™ DS Delivery System and Approval of the INOmax® (nitric oxide) Mini-Cylinder
– Company's next generation nitric oxide delivery system combines mini-cylinder technology, automation, integration, and interaction into one device1 – – The INOmax EVOLVE DS also earned recognition from the Human Factors and Ergonomics Society (HFES) for this year's innovative design –...Mallinckrodt Announces Submission of 510(k) to the U.S. FDA for Inhaled Nitric Oxide Delivery System
— If 510(k) cleared, this next-generation investigational inhaled nitric oxide delivery system would be the latest in a long line of dual channel delivery systems building on Company's dedication to meeting clinicians' evolving needs — DUBLIN, Sept. 28, 2022 /PRNewswire/ -- Mallinckrodt...Mallinckrodt Raises Awareness of Critical Role Respiratory Therapists Play in Patient Care During Respiratory Care Week
STAINES-UPON-THAMES, United Kingdom, Oct. 21, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, is proud to celebrate Respiratory Care Week (October 20-26, 2019), and honor the role of respiratory therapists in providing critical care to patients in...Mallinckrodt Earns International Standard ISO 13485:2016 and Medical Device Single Audit Program (MDSAP) Certifications for INOmax® DSIR® Plus Nitric Oxide Delivery Systems
-- Achievements Indicate Mallinckrodt Meets Standards and Regulations Among the Most Comprehensive for Medical Device Quality Management Systems -- STAINES-UPON-THAMES, United Kingdom, Nov. 8, 2018 /PRNewswire/ -- Mallinckrodt Pharmaceuticals (NYSE: MNK), a leading global specialty pharmaceutical company, today announced it has received the International Organization for Standardization (ISO) 13485:2016 and Medical Device Single Audit Program (MDSAP) certifications following successful audits of
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding INOMAX hospitals
Sign Up For FreeTo access detailed company insights
Mallinckrodt Pharmaceuticals specializes in the production of INOmax, a nitric oxide gas for inhalation, primarily aimed at treating term and near-term neonates with hypoxic respiratory failure associated with pulmonary hypertension. Their offerings include innovative delivery systems that emphasize flexibility and automation, along with a comprehe... Read More
